Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:CPRX

Catalyst Pharmaceuticals Q2 2026 Earnings Report

Catalyst Pharmaceuticals logo
ProfileEarnings HistoryForecast

Catalyst Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$0.48
Beat/Miss
N/A
One Year Ago EPS
N/A

Catalyst Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$155.79 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Catalyst Pharmaceuticals Announcement Details

Quarter
Q2 2026
Date
8/5/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Catalyst Pharmaceuticals Earnings Headlines

Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
July 16, 2026  |  reuters.comhttps://www.reuters.com/legal/transactional/italys-angelini-pharma-completes-41-billion-state-backed-takeover-catalyst-2026-07-16/
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328252/0/en/angelini-pharma-completes-acquisition-of-catalyst-pharmaceuticals.html
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
September 13 at 1:00 AM  |  Profits Run (Ad)
Solaris Energy Infrastructure to join S&P SmallCap 600, replacing Catalyst Pharma
July 10, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/solaris-energy-infrastructure-to-join-s-p-smallcap-600-replacing-catalyst-pharma/ar-AA27Cf4p
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
July 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/santhera-notes-topline-results-catalyst-050000764.html
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319637/13009/en/vamorolone-demonstrates-on-target-glucocorticoid-activity-without-the-immunosuppression-characteristic-of-traditional-corticosteroids-at-clinical-doses.html
See More Catalyst Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catalyst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalyst Pharmaceuticals and other key companies, straight to your email.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

View Catalyst Pharmaceuticals Profile
Earnings Tools